{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:53:23Z","timestamp":1788839603092,"version":"build-2803163510"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.juro.2006.06.007","type":"journal-article","created":{"date-parts":[[2006,9,4]],"date-time":"2006-09-04T11:12:26Z","timestamp":1157368346000},"page":"1349-1353","source":"Crossref","is-referenced-by-count":60,"title":["Phase II Marker Lesion Study With Intravesical Instillation of Apaziquone for Superficial Bladder Cancer: Toxicity and Marker Response"],"prefix":"10.1097","volume":"176","author":[{"given":"Antoine G.","family":"van der Heijden","sequence":"first","affiliation":[{"name":"University Medical Centre Nijmegen, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula M.J.","family":"Moonen","sequence":"additional","affiliation":[{"name":"University Medical Centre Nijmegen, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik B.","family":"Cornel","sequence":"additional","affiliation":[{"name":"Twente Hospital Group Location SMT, Hengelo, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk","family":"Vergunst","sequence":"additional","affiliation":[{"name":"Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo M.","family":"de Reijke","sequence":"additional","affiliation":[{"name":"Academic Medical Centre, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"van Boven","sequence":"additional","affiliation":[{"name":"Maasziekenhuis, Boxmeer, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evert J.","family":"Barten","sequence":"additional","affiliation":[{"name":"Ziekenhuis Velp, Velp, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Puri","sequence":"additional","affiliation":[{"name":"Bradford Hospital National Health Service Trust, Bradford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coenraad K.","family":"van Kalken","sequence":"additional","affiliation":[{"name":"NDDO Research Foundation, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alfred","family":"Witjes","sequence":"additional","affiliation":[{"name":"University Medical Centre Nijmegen, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2006.06.007_bib1","series-title":"Cancer Incidence in Five Continents","author":"Parkin","year":"2003"},{"key":"10.1016\/j.juro.2006.06.007_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/canjclin.55.1.10","article-title":"Cancer statistics, 2005","volume":"55","author":"Jemal","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.juro.2006.06.007_bib3","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.06.007_bib4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3727\/095535491820873164","article-title":"The role of NAD(P)H","volume":"3","author":"Walton","year":"1991","journal-title":"Cancer Commun"},{"key":"10.1016\/j.juro.2006.06.007_bib5","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/01.ju.0000146274.85012.e1","article-title":"Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder","volume":"173","author":"van der Heijden","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.06.007_bib6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000473784","article-title":"Chemoresection in Ta-T1 bladder cancer","volume":"29","author":"Bono","year":"1996","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2006.06.007_bib7","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1464-410X.1996.09002.x","article-title":"Phase II trials in Ta, T1 bladder cancer. The marker tumour concept","volume":"77","author":"van der Meijden","year":"1996","journal-title":"Br J Urol"},{"key":"10.1016\/j.juro.2006.06.007_bib8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1159\/000049828","article-title":"Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions","volume":"40","author":"Oosterlinck","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2006.06.007_bib9","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0006-2952(99)00391-3","article-title":"Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice","volume":"59","author":"Loadman","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.juro.2006.06.007_bib10","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/0360-3016(92)90509-G","article-title":"Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents","volume":"22","author":"Workman","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.juro.2006.06.007_bib11","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/0959-8049(96)00120-7","article-title":"Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9","volume":"32A","author":"McLeod","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.juro.2006.06.007_bib12","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/S0022-5347(05)65624-8","article-title":"Distribution of DT-diaphorase and reduced nicotinamide adenine dinucleotide phosphate","volume":"166","author":"Li","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.06.007_bib13","article-title":"Phase I\/II clinical evaluation of intravesical EOquin (EO9) against superficial bladder cancer","volume":"96","author":"Phillips","year":"2005","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.juro.2006.06.007_bib14","first-page":"29","article-title":"Objective response of superficial bladder tumors to intravesical treatment (including review of response of marker lesions)","volume":"378","author":"Bouffioux","year":"1992","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.juro.2006.06.007_bib15","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/1097-0142(19930901)72:5<1749::AID-CNCR2820720539>3.0.CO;2-8","article-title":"Intravesical 4\u2032-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guerin. A controlled prospective study on the prophylaxis of superficial bladder cancer","volume":"72","author":"Melekos","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2006.06.007_bib16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00005392-200102000-00011","article-title":"The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder","volume":"165","author":"Mack","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.06.007_bib17","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0090-4295(97)00625-0","article-title":"Intravesical electromotive administration of drugs for treatment of superficial bladder cancer","volume":"51","author":"Brausi","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.juro.2006.06.007_bib18","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/S0022-5347(17)42052-0","article-title":"Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder","volume":"140","author":"Heney","year":"1988","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.06.007_bib19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000472938","article-title":"Intravesical chemoresection with 4\u2019-epi-doxorubicin in patients with superficial bladder tumors","volume":"14","author":"Calais da Silva","year":"1988","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2006.06.007_bib20","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1159\/000052521","article-title":"The use of valrubicin for the chemoresection of superficial bladder cancer\u2014a marker lesion study","volume":"39","author":"Newling","year":"2001","journal-title":"Eur Urol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534706013747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534706013747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2006.06.007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T01:43:01Z","timestamp":1651196581000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2006.06.007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["10.1016\/j.juro.2006.06.007"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2006.06.007","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}